Robert Hershberg, M.D., Ph.D.

Director

Dr. Robert Hershberg, MD., Ph.D. is a founder of VentiRx Pharmaceuticals, and currently serves as the Executive Vice President and Chief Medical Officer as well as a member of the Board of Directors. Prior to VentiRx, Dr. Hershberg served as the Senior Vice President and Chief Medical Officer at Dendreon Corporation (NASDAQ: DNDN), a biotechnology company based in Seattle, WA, developing immunotherapy approaches for cancer. In this capacity, Dr. Hershberg led the Clinical, Regulatory, and Biometrics groups, focusing on the development of Provenge™ in metastatic prostate cancer.

Prior to joining Dendreon, Dr. Hershberg was the Vice President of Medical Genetics at Corixa Corporation (which was subsequently acquired by GSK). He led a research group focused on innate immunity and inflammatory disease, with a particular emphasis on Toll-like receptors (TLRs), and was an active member of the clinical development team for various products.

Prior to joining Corixa, Dr. Hershberg was an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women's Hospital, in Boston, MA. He completed his undergraduate degree in molecular biology at UCLA, his MD at UCLA, and his PhD in Biology at the Salk Institute. He is clinically-boarded in Medical Genetics, and holds current clinical and research faculty positions at the University of Washington School of Medicine.